Evidence map›Paper›PMID 42233671›Full record

ArticlemBio2026

Identification and characterization of a SARS-CoV-2 M

Yao Ma, Chengjin Ye, R Rahisuddin, Sara H Mahmoud, Anastasija Cupic, Ahmed Magdy Khalil, Esteban Castro, Nathaniel Jackson, Mahmoud Bayoumi, Shailee Arya and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Yao Ma *Texas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0003-0815-7910
Chengjin Ye *Texas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0002-1934-9494
R RahisuddinGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas, USA.
Sara H MahmoudTexas Biomedical Research Institute, San Antonio, Texas, USA.
Anastasija CupicGraduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ahmed Magdy KhalilTexas Biomedical Research Institute, San Antonio, Texas, USA.
Esteban CastroTexas Biomedical Research Institute, San Antonio, Texas, USA.
Nathaniel JacksonTexas Biomedical Research Institute, San Antonio, Texas, USA.
Mahmoud BayoumiTexas Biomedical Research Institute, San Antonio, Texas, USA.
Shailee AryaGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas, USA.
Yogesh K GuptaGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-6551-1827
Richard K PlemperCenter for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.ORCID 0000-0003-2034-2107
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0001-7084-0804

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Project 6 - Development of Antivirals against AlphavirusesU19AI171403 · NIAID · EMORY UNIVERSITY · PI George Robert Painter, Richard K. Plemper · 2022 to 2026
$59.7M
Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2R01AI161363 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GUPTA, YOGESH K · 2021 to 2025
$3.2M
Science as a Team Sport: Leveling the playing field and setting the rules of engagement.T32GM148752 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GRIFFITH, ANN VENABLES, OYAJOBI, BABATUNDE OLUKAYODE · 2023 to 2024
$874k
NIAID NIH HHS R01 AI161363NIAID NIH HHS U19 AI171403NIGMS NIH HHS T32 GM148752NIH HHS 75N93021C00014
6 · The paper itself

Abstract

Ensitrelvir is an antiviral drug that specifically targets the conserved main protease (M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesDrug Resistance, ViralSARS-CoV-2AlanineAnimalsChlorocebus aethiopsHumansIndazolesLactamsLeucineMutationSequence DeletionSulfonic AcidsTriazinesTriazolesAlanineAntiviral AgentsCoronavirus 3C ProteasesensitrelvirGC376IndazolesLactamsLeucineSulfonic AcidsTriazinesTriazolesattenuated virusdrug resistance mutationsensitrelvirG23 deletionSARS-CoV-2

Identifiers

PMID42233671
PMCPMC13343909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.